Aim: We determined whether subclassification of short small for gestational age (SGA) children according to birth anthropometrics could delineate different patterns in gestation, delivery, postnatal growth, response to growth hormone (GH) treatment and parental height. Methods: 201 short SGA children were divided into three groups, SGAL, SGAL+W and SGAL+W+HC, according to birth length (L), weight (W) and head circumference (HC) ≤–2.00 standard deviation score (SDS). Results: SGAL+W+HC children were born after the shortest gestational age and more often by caesarean section than SGAL children (36.3 vs. 38.1 weeks, 68.4 vs. 24.4%). SGAL+W children had an intermediate pattern and experienced most gestational hypertension (p = 0.01). At birth, SGAL+W+HC children were shorter than SGAL or SGAL+W (–4.12 vs. –2.67 and –3.72 SDS, p ≤ 0.001). During the first 3 years of life, SGAL+W+HC children exhibited an increased growth in height (0.98 SDS) and HC (1.28 SDS) than SGAL (height, –0.06 SDS; HC, –0.30 SDS) and SGAL+W (height, 0.62 SDS; HC, –0.31 SDS). However, HC SDS remained smaller for SGAL+W+HC than the other groups at age 3. The groups did not differ in growth response during GH treatment. SGAL children tended to have shorter parents and target height than SGAL+W+HC children. Conclusions: Our study shows that subclassification of short SGA children might be a useful method for investigating SGA children as the subgroups revealed a different gestation, delivery and postnatal growth pattern. Response to GH treatment was not different between the groups.

1.
Hokken-Koelega AC, De Ridder MA, Lemmen RJ, Den Hartog H, De Muinck Keizer-Schrama SM, Drop SL: Children born small for gestational age: do they catch up? Pediatr Res 1995;38:267–271.
2.
Albertsson-Wikland K, Karlberg J: Natural growth in children born small for gestational age with and without catch-up growth. Acta Paediatr 1994;399(suppl):64–71.
3.
European Health For All Database (HFA-DB). Available at: www.euro.who.int/hfadb
4.
Arends NJ, Boonstra VH, Hokken-Koelega AC: Head circumference and body proportions before and during growth hormone treatment in short children who were born small for gestational age. Pediatrics 2004;114:683–690.
5.
Sas TC, Gerver WJ, de Bruin R, Mulder PG, Cole TJ, De Waal W, Hokken-Koelega AC: Body proportions during 6 years of GH treatment in children with short stature born small for gestational age participating in a randomised, double-blind, dose-response trial. Clin Endocrinol (Oxf) 2000;53:675–681.
6.
Sas T, Mulder P, Hokken-Koelega A: Body composition, blood pressure, and lipid metabolism before and during long-term growth hormone treatment in children with short stature born small for gestational age either with or without growth hormone deficiency. J Clin Endocrinol Metab 2000;85:3786–3792.
7.
Sas T, Mulder P, Aanstoot HJ, Houdijk M, Jansen M, Reeser M, Hokken-Koelega A: Carbohydrate metabolism during long-term growth hormone treatment in children with short stature born small for gestational age. Clin Endocrinol (Oxf) 2001;54:243–251.
8.
Van Pareren Y, Mulder P, Houdijk M, Jansen M, Reeser M, Hokken-Koelega A: Adult height after long-term, continuous growth hormone treatment in short children born small for gestational age: results of a randomized, double-blind, dose-response growth hormone trial. J Clin Endocrinol Metab 2003;88:3584–3590.
9.
Van Pareren YK, Duivenvoorden HJ, Slijper FS, Koot HM, Hokken-Koelega AC: Intelligence and psychosocial functioning during long-term growth hormone therapy in children born small for gestational age. J Clin Endocrinol Metab 2004;89:5295–5302.
10.
Usher R, McLean F: Intrauterine growth of live-born Caucasian infants at sea level: standards obtained from measurements in 7 dimensions of infants born between 25 and 44 weeks of gestation. J Pediatr 1969;74:901–910.
11.
Fredriks AM, van Buuren S, Burgmeijer RJ, Meulmeester JF, Beuker RJ, Brugman E, Roede MJ, Verloove-Vanhorick SP, Wit JM: Continuing positive secular growth change in The Netherlands 1955–1997. Pediatr Res 2000;47:316–323.
12.
Gerver WJ, de Bruin R: Paediatric Morphometrics, a Reference Manual, ed 2. Maastricht, University Press Maastricht, 2001.
13.
Roede MJ, van Wieringen JC: Growth diagrams 1980: Netherlands Third Nationwide Survey. Tijdschr Soc Gezondheidsz 1985;63(suppl):1–34.
14.
Mamelle N, Boniol M, Riviere O, Joly MO, Mellier G, Maria B, Rousset B, Claris O: Identification of newborns with fetal growth restriction in weight and/or length based on constitutional growth potential. Eur J Pediatr 2006;165:717–725.
15.
Woods KA, Camacho-Hubner C, Savage MO, Clark AJ: Intrauterine growth retardation and postnatal growth failure associated with deletion of the insulin-like growth factor I gene. N Engl J Med 1996;335:1363–1367.
16.
Johnston LB, Dahlgren J, Leger J, Gelander L, Savage MO, Czernichow P, Wikland KA, Clark AJ: Association between insulin-like growth factor I polymorphisms, circulating insulin-like growth factor I, and pre- and postnatal growth in two European small for gestational age populations. J Clin Endocrinol Metab 2003;88:4805–4810.
17.
Walenkamp MJ, Karperien M, Pereira AM, Hilhorst-Hofstee Y, van Doorn J, Chen JW, Mohan S, Denley A, Forbes B, van Duyvenvoorde HA, van Thiel SW, Sluimers CA, Bax JJ, de Laat JA, Breuning MB, Romijn JA, Wit JM: Homozygous and heterozygous expression of a novel insulin-like growth factor-I mutation. J Clin Endocrinol Metab 2005;90:2855–2864.
18.
Abuzzahab MJ, Schneider A, Goddard A, Grigorescu F, Lautier C, Keller E, Kiess W, Klammt J, Kratzsch J, Osgood D, Pfäffle R, Raile K, Seidel B, Smith RJ, Chernausek SD, Intrauterine Growth Retardation (IUGR) Study Group: Insulin-like growth factor I receptor mutations resulting in intrauterine and postnatal growth retardation. N Engl J Med 2003;349:2211–2222.
19.
Kawashima Y, Kanzaki S, Yang F, Kinoshita T, Hanaki K, Nagaishi J, Ohtsuka Y, Hisatome I, Ninomoya H, Nanba E, Fukushima T, Takahashi S: Mutation at cleavage site of insulin-like growth factor receptor in a short-stature child born with intrauterine growth retardation. J Clin Endocrinol Metab 2005;90:4679–4687.
20.
Dos Santos C, Essioux L, Teinturier C, Tauber M, Goffin V, Bougneres P: A common polymorphism of the growth hormone receptor is associated with increased responsiveness to growth hormone. Nat Genet 2004;36:720–724.
21.
Arends N, Johnston L, Hokken-Koelega A, van Duijn C, de Ridder M, Savage M, Clark A: Polymorphism in the IGF-I gene: clinical relevance for short children born small for gestational age. J Clin Endocrinol Metab 2002;87:2720.
22.
Lundgren EM, Cnattingius S, Jonsson B, Tuvemo T: Intellectual and psychological performance in males born small for gestational age with and without catch-up growth. Pediatr Res 2001;50:91–96.
23.
Frisk V, Amsel R, Whyte HE: The importance of head growth patterns in predicting the cognitive abilities and literacy skills of small-for-gestational-age children. Dev Neuropsychol 2002;22:565–593.
24.
Brandt I, Sticker EJ, Lentze MJ: Catch-up growth of head circumference of very low birth weight, small for gestational age preterm infants and mental development to adulthood. J Pediatr 2003;142:463–468.
25.
Gale CR, O’Callaghan FJ, Godfrey KM, Law CM, Martyn CN: Critical periods of brain growth and cognitive function in children. Brain 2004;127:321–329.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.